Radius Health, Inc.
Radius Health is driven by people who exhibit passion and commitment to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. We are a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product, TYMLOS (abaloparatide) Injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. The Radius clinical pipeline includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Radius' RAD140, a non-steroidal, selective androgen receptor modulator (SARM), is under investigation for potential use in hormone receptor positive breast cancer. Radius was founded in 2003 and has locations in Waltham and Cambridge, Massachusetts, Parsippany, New Jersey, and Wayne, Pennsylvania. If you think you have the same passion and commitment we have, check out www.radiuspharm.com.
Pharmaceuticals
200 - 500
Waltham, MA, United States
About

Radius Health is driven by people who exhibit passion and commitment to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. We are a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases.

Radius' lead product, TYMLOS (abaloparatide) Injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe.

The Radius clinical pipeline includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Radius' RAD140, a non-steroidal, selective androgen receptor modulator (SARM), is under investigation for potential use in hormone receptor positive breast cancer.

Radius was founded in 2003 and has locations in Waltham and Cambridge, Massachusetts, Parsippany, New Jersey, and Wayne, Pennsylvania.

If you think you have the same passion and commitment we have, check out www.radiuspharm.com.

Site Traffic
  • 2517655 Global Rank
  • 502910
    United States
Traffic Sources
  • Search
    54.83%
  • Direct
    42.13%
  • Mail
    1.66%
  • Referrals
    1.38%
  • Display
    0.00%
  • Social
    0.00%
Powered by
Alexa Traffic Data
Global Rank 468,166
5,275,542
United States Rank 10,475
34,251
United States Page Views 71.0%
14.5%
Top Countries
Top Search Keywords
  • Français
  • Actualité
  • Journaux
Ad Intelligence
  • Standard
    100.00%
Ads Seen Recently
10
Longest Running Ad
Radius Health, Inc.
Device
Desktop
Dimensions
728x90
Radius Health, Inc. receives up to 0.04M pageviews per day.

They are headquartered at Waltham, MA, United States, and have 5 advertising & marketing contacts listed on Kochava. Radius Health, Inc. works with Advertising technology companies such as ExactTarget, DoubleClick.Net.